Fig. 3

circEHD2 promotes the growth of RCC cells in vivo. A and B, Images of xenograft tumors after injection of OSRC-2 cells transfected with sh-NC and sh-circEHD2#1 (n = 4/group). C, The volumes of subcutaneous tumors were recorded once a week for four consecutive weeks. D, The subcutaneous tumor weights were weighed at the endpoint time of the experiment. E, The orthotopic tumor growth in the left subrenal capsule was monitored weekly by in vivo bioluminescence imaging(n = 6/group). F, The bioluminescence signals of orthotopic tumors were measured by mean photon counts. G, Gross appearance of orthotopic tumor after left subrenal capsule injection with sh-NC and sh-circEHD2#1 (n = 6/group). H, Images of HE and IHC staining by anti-Ki67 antibody in orthotopic tumors (n = 6/group). Scale bars: 50 μm. I, H-score of Ki67 in orthotopic tumors (n = 6/group). *, P < 0.05; **, P < 0.01